Hypoglycemia and Cardiac Arrhythmias in Type 1 Diabetes (Hypo-Heart-1)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2900
- Clinical Metabolic Physiology, SDCC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed and written consent
- Type 1 diabetes diagnosed according to the criteria of the World Health Organization (WHO)
- Age 18-70 years
- Insulin treatment for ≥3 years
Exclusion Criteria:
- Arrhythmia diagnosed prior to the screening visit
- Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion
- Severe heart failure (left ventricular ejection fraction <25%)
- Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
- Thyroid dysfunction (except for well-regulated eltroxin substituted myxoedema)
- Anemia (male: hemoglobin <8.0; female: hemoglobin <7.0 mmol/l)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Clamp group
24 patients with type 1 diabetes.
|
Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively.
Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp.
The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes.
The two clamp days will be separated by at least 30 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
QTc prolongation.
Time Frame: 255 minutes
|
Difference in mean corrected QT interval (QTc) prolongation during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
QTd dispersion.
Time Frame: 255 minutes
|
Difference in QT dispersion (QTd) during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
|
Atrial ectopic beats.
Time Frame: 255 minutes
|
Difference in atrial ectopic beats (prematurity threshold 30%),during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
|
Bradycardia
Time Frame: 255 minutes
|
Difference in non-clinically significant bradycardia (≤45 bpm for 5 seconds) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
|
Ventricular premature beats
Time Frame: 255 minutes
|
Difference in ventricular premature beats during hyperglycaemia compared to euglycaemia both preceded by insulin-induced hypoglycaemia
|
255 minutes
|
|
Glucagon response
Time Frame: 255 minutes
|
Differences in glucagon response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
|
Catecholamine response
Time Frame: 255 minutes
|
Differences in catecholamine response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
|
Growth hormone response
Time Frame: 255 minutes
|
Differences in growth hormone response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
|
Cortisol response
Time Frame: 255 minutes
|
Differences in cortisol responses during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia
|
255 minutes
|
|
Haemodynamic regulation.
Time Frame: 255 minutes
|
Differences in haemodynamic regulation (measured by echocardiography) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
|
Inflammatory response
Time Frame: 255 minutes
|
Differences in markers of inflammation (high-sensitive C-reactive peptide (hs-CRP) and interleukin 6 (IL-6)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
|
Oxidative stress markers (8-iso-PGF2α)
Time Frame: 255 minutes
|
Differences in markers of oxidative stress (8-iso prostaglandin F2α (8-iso-PGF2α)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
|
Oxidative stress markers (8-oxoGuo)
Time Frame: 255 minutes
|
Differences in markers of oxidative stress (8-oxo-7,8-dihydroguanosine (8-oxoGuo)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia
|
255 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Tina Vilsbøll, MD, DMSc, Steno diabetic centre (SDCC)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Heart Diseases
- Metabolic Diseases
- Autoimmune Diseases
- Immune System Diseases
- Glucose Metabolism Disorders
- Hypoglycemia
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Arrhythmias, Cardiac
- Physiological Effects of Drugs
- Hypoglycemic Agents
Other Study ID Numbers
Other Study ID Numbers
- H-18034040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.